Drug facts
MoleculeClopidogrel (Plavix)
Generics already compete: 15 makers on the market. 22 A-rated products from 15 makers substitute at the counter.
Plavix was first approved by the FDA on 11/17/1997 under NDA 020839; the application holder is Sanofi Aventis US LLC.
The latest NADAC for CLOPIDOGREL 75 MG TABLET is $0.05 per unit (as of 10/28/2026).
Holder Sanofi Aventis US LLCApplication NDA 020839Approved 11/17/1997
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Plavix patent listed in the Orange Book Orange Book
02Competition
- Generics
- 15 generic makers Orange Book
- First generic approved
- 01/14/2008 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Clopidogrel profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.05 per unitCLOPIDOGREL 75 MG TABLET, as of 10/28/2026 CMS NADAC
- Latest recall
- 03/23/2023Class II, Clopidogrel Tablets USP, Preferred Pharmaceuticals, Inc. FDA enforcement
04Product
- Application holder
- Sanofi Aventis US LLC Orange Book
- Application
- NDA 020839 Orange Book
- First approved
- 11/17/1997 Orange Book
- Dosage forms
- tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.